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Abstract
We investigated the combinatorial effects of different doses of dietary soy isoflavones (SI) and fructooligosaccharide (FOS) in a rat model of 
colon cancer. We hypothesized that increased bioavailability of SI metabolites due to dietary FOS may increase production of bioactive equol and 
affect colon carcinogenesis in a dose-dependent manner. Sprague-Dawley male rats were injected with 12-dimethylhydrazine (DMH) and were provided
experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg of diet and 6% FOS for 12 weeks. The number of aberrant crypt foci
(ACF) and the expression of cyclooxygenase-2 (COX-2) in colonic tissues were significantly decreased in the 6% FOS-fed groups compared to 
the control group. Gut transit time and fecal pH were significantly lower, and fecal concentrations of bifidobacteria were increased with 6% FOS.
However, dietary SI supplementation in combination with 6% dietary FOS did not affect ACF formation or COX-2 expression. Plasma equol concentrations
were dose-dependently increased by supplementation of SI up to 500 mg/kg of diet. In conclusion, SI supplementation up to 500 mg/kg of diet
appeared to have no additive beneficial effects in rats with chemically-induced colon cancer that were fed 6% FOS, although plasma equol was 
dose-dependently increased.
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Introduction1)
Diet and behavior underlie the etiology of various types of 
cancer. Specifically, colon and rectal cancer occurrence is 
ten-fold higher in developed countries than in non-developed 
countries (WHO, 2003), and diet-related factors may account for 
up to 80% of this regional difference in cancer occurrence 
(Cummings & Bingham, 1998).  Consumption of foods contain-
ing soy isoflavones (SI) such as genistein and daidzein has been 
weakly associated with reduced colon cancer risk (Cotterchio et 
al., 2006; Messina & Bennink, 1998). Dietary SI and estrone 
were shown to reduce colon tumorigenesis in azoxymethane- 
treated ovariectomized mice (Guo et al., 2004); however, the 
bioavailability of such isoflavones is influenced by their chemical 
form in foods, their hydrophobicity and susceptibility to 
degradation, the microbial flora of the consumer, and the food 
matrix (Birt et al., 2001). In particular, equol, a product derived 
from intestinal bacterial metabolism (Atkinson et al., 2004; 
Setchell et al., 2002), displays more estrogenic potency than its 
precursor isoflavone, daidzein (Atkinson et al., 2005). Never-
theless, the inter-relationships and effects of SI and colonic 
microflora on colon cancer are unclear.
Evidence from a wide range of sources supports the notion 
that colonic microflora are involved in the etiology of colon 
cancer (Lim et al., 2005; Onoue et al., 1997). Dietary 
fructooligosaccharide (FOS) improves the gut ecosystem by 
increasing bifidobacteria and dose-dependently shortens gut 
transit time in 1,2-dimethylhydrazine (DMH)-treated rats (Sung 
et al., 2006). Specifically, FOS alters the bioavailability of 
daidzein and genistein (Uehara et al., 2001) and inhibits the 
formation of aberrant crypt foci (ACF) (Pierre et al., 1997). In 
a previous study, we observed that FOS dose-dependently 
suppressed ACF formation and that supplementation of the diet 
with SI (1,000 mg/kg) resulted in an additional suppressive effect 
on colon carcinogenesis (Sung & Choi, 2008). 
Therefore, we hypothesized that production of SI metabolites 
such as equol in the presence of FOS may increase the relative 
proportion of bioactive isoflavones and alter the expression of 
colon cancer biomarkers. Here we assessed the dose-response 
effectiveness of SI fed concomitantly with 6% FOS on ACF 
formation, cyclooxygenase-2 (COX-2) expression in colonic 
tissues, gut ecosystem, and plasma equol concentration in a rat 
model of colon cancer. 
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Table 1. Experimental diet compositions (g/kg diet) 
Ingredients Normal Control SI-0
FOS
SI-10
FOS
SI-50
FOS
SI-150
FOS
SI-500
FOS
Cornstarch 509.5 509.5 509.5 509.45 509.25 508.75 507
Casein 200 200 200 200 200 200 200
Sucrose
1) 120 120 60
(10.30)
60
(10.30)
60
(10.30)
60
(10.30)
60
(10.30)
Soybean oil 70 70 70 70 70 70 70
F i b e r 5 05 05 05 05 05 05 0
Mineral mix 35 35 35 35 35 35 35
Vitamin mix 10 10 10 10 10 10 10
L-Cystine 3 3 3 3 3 3 3
Choline bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Soy isoflavones
2) 0 0 0 0.05 0.25 0.75 2.5
Fructooligosaccharide
3) 00 60
(146.3)
60
(146.3)
60
(146.3)
60
(146.3)
60
(146.3)
Total 1,000 1,000 1,000 1,000 1,000 1,000 1,000
1) Sucrose and glucose contained in the fructooligosaccharide (FOS) syrup account 
for  the  difference  (actual  amount  used  shown  in  parentheses). 
2) Amount  of  soy  isoflavone  powder  containing  20.23%  aglycone  forms  (daidzein 
8.18%,  glycitein  9.85%,  and  genistein  2.20%).
3) Fructooligosaccharide  syrup  (actual  amount  used  shown  in  parentheses)  was 
composed  of  41%  fructooligosaccharide,  25%  water,  glucose,  and  sucrose.
Methods and Materials 
Animals and diets
Four week-old male Sprague Dawley rats (n = 70) were 
procured from Daehan Biolink Co. (Chungbuk, Korea) and were 
acclimated to the facility for 1 week. Water and standard rodent 
chow (Samyang Feed Co., Gangwon, Korea) were provided ad 
libitum. Rats (n=60) were injected subcutaneously twice per week 
for 4 weeks with DMH (20 mg/kg body weight) in ethylene-
diaminetetraacetic acid (EDTA, 1 mM, pH 6.7) to induce colon 
cancer. Ten rats were injected with the equivalent volume of 
EDTA solution for use as normal rats. The DMH-injected rats 
were divided into six groups of ten rats each and were fed 
different experimental diets (Table 1) for 12 weeks.
The AIN93-based experimental diets (American Institute of 
Nutrition, 1993) contained 0, 10, 50, 150, or 500 mg of SI per 
kg of chow and were given concomitantly with 6% FOS. The 
ingredients for the AIN93 diets were purchased from Harlan 
Teklad (Madison, WI, USA). The FOS (CJ Co., Seoul, Korea) 
had 3-4 degrees of polymerization and consisted of 37% GF2, 
16% GF3, and 2% GF4 on a dry weight basis. The soy isoflavones 
(Shindongbang Co., Seoul, Korea) contained 20.23% aglycones 
(8.18% daidzein, 9.85% glycitein, and 2.20% genistein). 
The rats were weighed twice per week. The protocols and use 
of rats were approved by the Animal Care and Use Committee 
of Daegu University (Gyeongsan, Korea). 
Measurement of fecal pH and gut transit time 
Fresh feces collected at week 12 of the experimental diet were 
diluted four times with distilled water, and a  pH electrode 
(ORION model 420A; Thermo Electron Co., Waltham, MA, 
USA) that was completely immersed in the sample solution was 
used to measure the pH. The gut transit time was determined 
by measuring the time of the first appearance of carmine red 
in the feces following the addition of 0.5% carmine red to the 
diet. 
Measurement of fecal microflora 
At week 12 of the experimental diet, fresh feces were collected, 
placed in sterilized phosphate buffer, homogenized, and diluted. 
The fecal strains of bifidobacteria, lactobacilli, and bacteroides 
were cultured using Bifidobacterium-selective (BS) agar, Man 
Rogosa and Sharpe (MRS) agar (Merck, Darmstadt, Germany), 
and vancomycin-added (VA) medium (Ji et al., 1994), 
respectively. The culture dishes were incubated at 37℃ under 
anaerobic conditions using Anaerocult A (Merck) for 72 h. 
Colonies characteristic of each bacterial group were visually 
counted, and the results were expressed as log10 colony-forming 
units (CFU) per gram of wet weight. Total anaerobes and aerobes 
were cultured in glucose-liver-blood (BL) agar under anaerobic 
and aerobic conditions, respectively, at 37℃ for 72 h, and the 
number of colonies formed was recorded.
Measurement of plasma concentration of equol 
Plasma equol glucuronides and sulfates were hydrolyzed, and 
equol was extracted for time-resolved fluorescence (TR-FIA; 
Brouwers et al., 2003) using an equol kit (Labmaster Ltd, Turku, 
Finland). All reagents and samples were brought to room 
temperature (20-25℃) before use. All reagents were purchased 
from Wallac Oy (Turku, Finland), and the TR-FIA for equol 
was performed as follows. An aliquot of 200 μL of acetate buffer 
(0.1 M, pH 5.0, containing 0.2 U/mL of β-glucuronidase and 
2 U/mL of sulfates) was added to tubes containing 200 μL of 
plasma. After mixing, the samples were incubated overnight at 
37℃. The following day, the free equol was extracted with 1.5 
mL diethyl ether by careful mixing of the two phases for 3 
minutes. After thawing, the water phase was frozen in a dry 
ice-ethanol mixture, and the ether phase was re-extracted with 
ether in a disposable glass tube; the ether phases were combined 
and evaporated to dryness at 45℃ in a water bath. Assay buffer 
(200 μL) was added to the tubes, and, after careful mixing, 20 
μL of the solution corresponding to 20 μL of the original plasma 
sample were taken for TR-FIA. Its equol concentration was 
determined by a Victor 1420 multi-label counter with software 
version 2.0 for fluorescence measurements (Perkin Elmer Life 
and Analytical Sciences, Inc., Finland). 
Quantification of ACF 
Colons were removed, flushed with ice-cold saline, and slit 
open from the anus to the cecum on a cold plate. The distal Hye-Young Sung & Young-Sun Choi 57
Table 3. Effects of soy isoflavones (SI) and fructooligosaccharide (FOS) on fecal microflora of DMH-treated rats 
Group
Bifidobacteria Lactobacilli Bacteroides Total anaerobes Total aerobes
log10 CFU/g
Normal 5.798 ± 0.199
b 6.513 ± 0.161
b 6.766 ± 0.150
b 6.864 ± 0.123
b 6.962 ± 0.170
Control 5.918 ± 0.157
b 6.560 ± 0.181
b 6.955 ± 0.269
b 6.913 ± 0.224
b 7.052 ± 0.219
Control-FOS 7.574 ± 0.175
a 7.106 ± 0.254
ab 7.916 ± 0.218
a 8.122 ± 0.201
a 7.147 ± 0.307
SI 10-FOS 7.473 ± 0.286
a 7.603 ± 0.342
a 8.458 ± 0.167
a 8.355 ± 0.195
a 6.867 ± 0.485
SI 50-FOS 7.145 ± 0.246
a 7.423 ± 0.297
a 8.081 ± 0.285
a 8.015 ± 0.221
a 7.419 ± 0.265
SI 150-FOS 7.036 ± 0.219
a 7.628 ± 0.283
a 8.247 ± 0.150
a 8.498 ± 0.134
a 7.352 ± 0.351
SI 500-FOS 7.344 ± 0.238
a 7.724 ± 0.220
a 8.293 ± 0.153
a 8.222 ± 0.179
a 6.927 ± 0.344
DMH-treated  rats  were  fed  an  experimental  diet  that  contained  0,  10,  50,  150,  or  500  mg/kg  of  diet  SI  with  6%  FOS  for  12  weeks.  N o r m a l  a n d  c o n t r o l  r a t s  w e r e  f e d 
AIN-93  diet. 
Values  are  mean ± SEM  for  n=10. 
Values  in  the  same  column  with  different  superscripts  are  significantly  different  at  p < .05. 
Table 2. Effects of variable doses of soy isoflavones (SI) and of 6% fructooligosaccharide (FOS) on weight gain, food intake, and food efficiency ratio (FER) 
Group Initial weight (g) Final weight (g) Weight gain (g/day) Food intake* (g/day) FER* (g/100g)
Normal 361.60 ± 3.99 500.60 ± 14.07 1.59 ± 0.167
b 23.224 ± 0.632
a 6.979 ± 1.008
b
Control 339.10 ± 8.31 517.70 ± 10.78 2.04 ± 0.088
a 22.496 ± 0.376
ab 9.102 ± 0.422
a
SI 0-FOS 339.10 ± 8.40 479.80 ± 18.38 1.60 ± 0.124
b 21.338 ± 0.865
ab 7.476 ± 0.690
ab
SI 10-FOS 339.40 ± 8.54 478.70 ± 12.71 1.59 ± 0.054
b 21.169 ± 0.864
b 7.556 ± 0.406
ab
SI 50-FOS 339.60 ± 8.42 503.20 ± 10.34 1.87 ± 0.076
ab 21.460 ± 0.294
ab 8.719 ± 0.494
ab
SI 150-FOS 341.10 ± 8.28 489.70 ±  9.76 1.70 ± 0.851
b 20.911 ± 0.477
b 8.130 ± 0.332
ab
SI 500-FOS 340.30 ± 8.06 496.70 ± 16.50 1.78 ± 0.105
ab 20.847 ± 0.465
b 8.503 ± 0.516
ab
DMH-treated rats were fed an experimental diet that contained 0, 1 0 , 50 , 1 50 , o r 50 0  m g  S I p er kg o f d iet w ith  6 %  F O S  fo r 12  weeks. Normal and control rats were 
fed  AIN-93  diet. 
Values  are  mean ± SEM  for  n=10;  *n=5  (2  rats  pooled). 
Values  in  the  same  column  with  different  superscripts  are  significantly  different  at  p < .05. 
5-cm portion was excised, fixed in 10% buffered formalin 
solution for 24 h, and stained in 0.2% methylene blue solution 
for 10-15 min. The colons were placed mucosal side up on a 
microscopic slide and viewed using a microscope at 40× 
magnification. The numbers of ACF and aberrant crypts observed 
per focus were recorded (Bird, 1995).
COX-2 protein measurements 
The remaining portion of the colonic mucosa was scraped with 
a glass slide, frozen in liquid nitrogen, and stored at -70℃. The 
frozen mucosa was homogenized in lysis buffer [10 mM Tris 
(pH 7.4) buffer containing 5 mM EDTA, 150 mM NaCl, 1% 
Triton X-100, 10 mg/mL phenylmethylsulfonyl fluoride, 10 
mg/mL aprotinin, 10 mg/mL leupeptin, 5 mM phenanthroline, 
and 28 mM benzamidine-HCl] at 4℃ as described previously 
(Cho  et al., 2005). After 30 minutes, the cell lysates were 
centrifuged for 30 minutes at 8,000 × g at 4℃. The protein 
concentration of the supernatant was measured using BCA 
Protein Assay Reagent (Bio-Rad, Hercules, CA, USA). The 
proteins were separated by 10% SDS-PAGE and blotted 
electrophoretically onto nitrocellulose membranes (Bio-Rad). The 
membranes were washed with Tris-buffered saline (10 mM Tris, 
150 mM NaCl) that contained 0.05% Tween 20 (TBS-T) and 
blocked overnight at 4℃ in TBS-T buffer that contained 5% 
non-fat dried milk; they were subsequently incubated with rabbit 
anti-rat COX-2 polyclonal antibody (Abcam Ltd., Cambridge, 
UK) at room temperature for 2 h. After washing, the membranes 
were treated with goat polyclonal antibody to rabbit immun-
oglobulin G H & L (Cy5-conjugated; Abcam). The COX-2 
protein band densities were measured using a Fluorescence 
Imaging Analysis System (Typhoon 9200; Amersham Bios-
ciences, Piscataway, NJ, USA), and were expressed in densi-
tometry units. Immunoblot analysis using rabbit polyclonal anti-β
-actin (Abcam) was performed as a control for protein loading. 
Statistical analysis 
The results were expressed as means ± standard error of the 
mean (SEM). The SPSS release 15.0 software package (SPSS 
Inc., Chicago, IL, USA) was used for the statistical analyses. 
Differences of means between the groups that were significant 
at P < 0.05 using one-way analysis of variance (ANOVA) were 
tested by Duncan's multiple range tests at P < 0.05. 
Results 
Food intake and body weight gain 
Weight gains were lower and food intakes and food efficiency 
ratios tended to be lower in FOS-fed groups than in the control 
group (Table 2). Average intakes of SI based on body weight 
and the amount consumed per day were calculated from the 58 Dose-response assessment of anti-colon cancer efficacy of soy isoflavones
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Fig. 1. Effects of different doses of soy isoflavones (SI) on fecal pH and gut 
transit time in DMH-treated rats fed a diet containing fructooligosaccharide 
(FOS).  Rats  were fed  experimental diets  that  contained  0,  10,  50,  150, o r 5 0 0 
mg SI per kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 
10). 
a,b,cMeans  with  different  letters  are  significantly  different  from  each  other  by 
Duncan's  multiple  range  test  at  p< .05. 
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Fig. 2. Effects of different doses of soy isoflavones (SI) and fructooligo-
saccharide (FOS) on plasma equol concentrations in DMH-treated rats.
Rats were fed experimental diets that contained 0, 10, 50, 150, or 500 mg SI per 
kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 10). 
a,b,cMeans 
with different letters are significantly different from each other by Duncan's multiple 
range  test  at  p < .05. 
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Fig. 3. Effects of different doses of soy isoflavones (SI) and fructooligo-
saccharide (FOS) on numbers of (top) ACF and (bottom) ACF with four or more 
ACs per focus in the colons of DMH-treated rats. Rats were fed experimental 
diets that contained 0, 10, 50, 150, or 500 mg SI per kg diet and 6% FOS for 
12 weeks. Data are mean ± SE values (n = 10). 
a,bMeans with different letters are 
significantly different from each other by Duncan's multiple range test at p < .05. 
contents of SI in the experimental diet and from food intake. 
The intakes of total SI/kg body weight/day were 0.562, 2.821, 
8.319, and 27.679 mg from diets containing 10, 50, 150, and 
500 mg SI/kg of diet, respectively. The daily intake of SI per 
animal corresponded to 0.212, 1.073, 3.137, and 10.424 mg, 
respectively. Nevertheless, there were no significant differences 
among groups with increasing doses of SI (Table 2).
Fecal pH, fecal microflora, and gut transit time
After 12 weeks of feeding, fecal pH was significantly lower 
in rats fed 6% FOS diets than in rats from normal and control 
groups. Gut transit time was significantly reduced with FOS 
supplementation, except that containing 500 mg of SI, compared 
to the control diet (Fig. 1). However, SI supplementation did 
not affect fecal pH or gut transit time.
The dosage of SI did not affect the fecal microflora (Table 
3). Fecal concentrations of bifidobacteria, lactobacilli, bacter-
oides, and total anaerobes were significantly increased by FOS 
in diets, except lactobacilli concentration of the control-FOS 
group which was not significantly different from that of the 
control group. However, total aerobe concentrations were not 
significantly different among the groups. 
Plasma equol concentration
Plasma equol concentration was increased by SI in a 
dose-dependent manner up to 500 mg SI/kg diet (Fig. 2). The 
increase of plasma equol concentration at the dose of 10 mg 
SI/kg diet was insignificant compared to the control group. 
Concentrations of plasma equol were increased significantly with 
diets containing ≥50 mg SI/kg diet.Hye-Young Sung & Young-Sun Choi 59
COX-2
β-actin
b b
b b
b
a
b
0
100
200
300
400
500
Normal Control SI- 0 
FOS
SI-10
FOS
SI-50
FOS
SI-150
FOS
SI-500
FOS
D
e
n
s
i
t
o
m
e
t
e
r
 
u
n
i
t
s
Fig. 4. Effects of different doses of soy isoflavones (SI) and fructooligo-
saccharide (FOS) on COX-2 protein levels in colonic tissues of DMH-treated 
rats. Rats were fed experimental diets that contained 0, 10, 50, 150, or 500 mg 
SI per kg diet and 6% FOS for 12 weeks. Data are mean ± SE values (n = 10). 
a,bMeans with different letters are significantly different from each other by Duncan's 
multiple  range  test  at  p < .05. 
ACF and COX-2 protein in colonic tissues
The numbers of ACF and the numbers of ACF containing four 
or more crypts per focus were decreased significantly in rats fed 
FOS, regardless of the dose of SI, compared to control rats that 
were not fed FOS. SI at all doses did not affect the number 
of ACF in rats (Fig. 3). 
The expression level of COX-2 in the colonic mucosa was 
increased significantly in the control rats compared to the normal 
rats. Expression of COX-2 was significantly decreased with the 
addition of 6% FOS to the diet. However, the COX-2 expression 
level was not significantly affected by the addition of SI to the 
diet (Fig. 4). 
Discussion
We assessed whether dietary SI, given with 6% FOS, would 
affect the development of DMH-induced early lesions of colon 
cancer in rats. The FOS-supplemented diet lowered ACF 
formation as well as COX-2 expression in colonic tissues, and 
these results are in agreement with those of our previous study 
(Sung & Chioi, 2008). ACF are lesions in which more than two 
aberrant crypts are stuck together, and ACF with four or more 
AC per focus are reliable predictors of malignancy (Bird & Good, 
2000; Onoue et al., 1997). Overexpression of COX-2 has also 
been observed in colon tumors (Sheehan et al. 1999); in animal 
studies, blocking COX-2 chemically or by mutation causes a 
marked decrease in colon cancer development (Jacoby et al., 
2000; Oshima et al., 1996). Suppression of colon cancer 
biomarkers by 6% FOS in diets most likely occurred due to an 
improvement in the gut ecosystem. The FOS diet increased the 
proportion of bifidobacteria relative to total anaerobes, shortened 
gut transit time, and lowered gut pH. However, SI, even at high 
doses, did not affect the gut ecosystem or suppress biomarkers 
of colon cancer in rats. 
Nielsen and Williamson (2007) summarized data from 16 
studies on factors affecting the bioavailability of SI. According 
to their reports, the bioavailabilities of genistein and daidzein 
are increased by a rapid gut transit time and by low fecal 
digestion rates and are decreased by a fiber-rich diet; moreover, 
the summarized data suggest a reasonable correlation between 
the dose of SI and Cmax. In our study, feeding SI for 12 weeks 
resulted in a dose-dependent increase in the plasma equol 
concentration. The dose of 500 mg SI/kg diet corresponded to 
27.68 mg SI/ kg body weight. There are few reports dealing 
with association of dose of SI, plasma equol concentration, and 
health benefit of increased SI intake. According to Mathey et 
al. (2004), plasma equol concentrations increased dose-depen-
dently with SI up to 80 mg/kg body weight in ovariectomized 
rats fed experimental diets for 90 days. Furthermore, SI exhibited 
a bone-sparing effect at 20 mg/kg body weight/day, and addition 
of FOS to the diet significantly increased SI protection of the 
skeleton. Other work by Khalil et al. (2005) showed that 600 
mg and 1200 mg SI/kg diet resulted in a bone-sparing effect 
in orchidectomized aged male rats that were fed the experimental 
diets for 180 days. Collectively, these studies demonstrate that 
fairly high levels of SI (i.e., ≥20 mg/kg body weight) are 
required for beneficial effects on bone. Of these isoflavones, 
daidzein which is a direct precursor of equol appears to be more 
efficient for the prevention of bone loss than genistein as 
demonstrated by studies in castrated rats (Picherit et al., 2000). 
The average intake of total SI/kg body weight/day estimated 
from the diet containing 500 mg SI/kg was 27.679 mg (11.192 
mg daidzein and 2.955 mg genistein) in this study. The level 
is below NOAEL (no observed adverse effect level) of genistein, 
50 mg/kg body weight/day estimated by McClain et al. (2006) 
who carried out hazard analyses for acute, subchronic and chronic 
safety of genistein in rats.
Several epidemiological studies suggest that isoflavones in soy 
may prevent the development of colon cancer in humans 
(Adlercreutz, 1995; Birt et al., 2001; Cotterchio et al., 2006). 
Consistently, our previous study showed an independent suppr-
essive effect of SI (1,000 mg/kg of diet) on colon cancer 
biomarkers, and these effects of SI were also synergic with FOS.  
In contrast, Sørensen et al. (1998) reported that high amounts 
of SI (475 mg of total isoflavones per kg diet) in a Western-type 
high risk diet did not protect against intestinal tumor development 
in a relevant animal model such as Min mice. Furthermore, 
animal studies in general have not demonstrated an inhibitory 
effect by soy foods and isoflavones on the development of 
chemically-induced colorectal cancer (Messina & Bennink, 
1998). In a recent study by Daly et al. (2007), dietary SI 
(2 g/kg diet) did not provide protection against the development 
of preneoplastic colonic ACF in female rats. However, Guo et 
al., (2004) reported that estrone and SI have been associated with 60 Dose-response assessment of anti-colon cancer efficacy of soy isoflavones
lower incidences of colon tumors. 
Prebiotics such as FOS increase the intestinal bioavailability 
and affect the metabolism of isoflavones in rats (Uehara et al., 
2001), and increase microbial production of equol in mice (Ohta 
et al., 2002). In our study, even relatively large doses of SI (up 
to 500 mg/kg diet) that increased plasma equol did not offer 
additional protection to that provided by FOS against colon 
carcinogenesis. These results indicate that equol production from 
SI is not directly related to an inhibitory effect on colon cancer. 
It is plausible, however, that a favorable ecosystem of hosts that 
was maintained by the presence of 6% dietary FOS may negate 
the suppressive effect of SI on biomarkers of colon cancer. 
Further studies are required to delineate a potential role for SI 
themselves in colorectal carcinogenesis.
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